Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD)

Historical Holders from Q2 2016 to Q3 2025

Symbol
CLSD
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
76,991,404
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
114,849
Holdings value
$446,925
% of all portfolios
0%
Number of holders
3
Number of buys
1
Number of sells
-42
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WHITMORE BRADFORD T 8.6% $5,479,749 6,523,511 WHITMORE BRADFORD T 31 Dec 2024
Wiles Stephen Boyd 5.2% $3,362,985 4,003,553 Stephen Boyd Wiles 31 Mar 2025

Institutional Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 114,849 $446,925 -$11,767,308 $3.97 3
2025 Q2 9,385,817 $7,508,386 +$449,392 $0.8 44
2025 Q1 8,812,320 $8,089,826 -$576,881 $0.9179 44
2024 Q4 9,439,248 $8,968,508 -$10,832,435 $0.95 44
2024 Q3 10,051,240 $22,741,735 -$4,794,604 $1.27 49
2024 Q2 13,768,135 $17,898,695 -$2,355,975 $1.3 49
2024 Q1 15,525,337 $23,755,690 +$12,004,888 $1.53 52
2023 Q4 7,745,921 $9,061,432 +$2,013 $1.17 46
2023 Q3 7,836,345 $6,816,461 -$748,299 $0.8699 45
2023 Q2 8,593,115 $9,623,242 -$243,637 $1.12 53
2023 Q1 8,732,023 $9,079,704 -$467,329 $1.04 48
2022 Q4 9,132,339 $10,225,725 -$823,608 $1.12 52
2022 Q3 12,075,878 $13,644,782 -$1,864,424 $1.13 48
2022 Q2 13,703,062 $20,139,157 -$4,119,626 $1.47 49
2022 Q1 16,371,849 $37,492,487 -$12,563,251 $2.29 58
2021 Q4 21,007,920 $57,776,213 -$3,762,089 $2.75 63
2021 Q3 20,253,624 $121,519,006 +$4,442,643 $6 64
2021 Q2 19,661,979 $95,750,005 +$477,938 $4.87 52
2021 Q1 16,941,791 $41,846,002 +$8,585,588 $2.47 50
2020 Q4 14,258,408 $39,064,022 +$4,324,341 $2.74 39
2020 Q3 11,973,111 $18,437,012 -$35,532 $1.54 40
2020 Q2 11,782,473 $22,152,015 +$476,625 $1.88 44
2020 Q1 11,490,488 $19,549,099 +$5,927,577 $1.7 41
2019 Q4 7,942,384 $23,036,168 +$2,760,761 $2.9 44
2019 Q3 6,988,676 $4,404,981 +$1,247,959 $0.6301 29
2019 Q2 4,506,345 $4,379,055 -$1,789,200 $0.9716 42
2019 Q1 6,129,289 $8,458,399 -$8,173,128 $1.38 54
2018 Q4 12,782,054 $13,666,526 -$30,790,524 $1.07 66
2018 Q3 18,545,073 $114,045,615 -$22,905,647 $6.15 86
2018 Q2 20,384,198 $217,946,411 +$7,948,569 $10.69 83
2018 Q1 19,639,635 $210,734,586 +$82,090,791 $10.73 79
2017 Q4 12,327,157 $86,290,610 -$5,570,945 $7 52
2017 Q3 13,088,877 $114,100,428 -$1,664,519 $8.74 49
2017 Q2 13,285,650 $121,007,259 +$12,513,466 $9.11 51
2017 Q1 11,991,070 $95,220,779 +$3,303,637 $7.94 58
2016 Q4 11,869,846 $106,108,957 +$35,189,140 $8.94 62
2016 Q3 7,930,817 $137,597,118 +$10,460,494 $17.35 30
2016 Q2 7,534,407 $52,817,000 +$52,817,000 $7.01 16